What is Zacks Research’s Forecast for MetaVia Q1 Earnings?

MetaVia Inc. (NASDAQ:MTVA) – Equities research analysts at Zacks Research issued their Q1 2026 EPS estimates for MetaVia in a research note issued on Tuesday, March 31st. Zacks Research analyst D. Bautz expects that the company will post earnings per share of ($0.74) for the quarter. The consensus estimate for MetaVia’s current full-year earnings is ($3.90) per share. Zacks Research also issued estimates for MetaVia’s Q2 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($1.53) EPS and FY2028 earnings at ($1.43) EPS.

A number of other equities research analysts have also weighed in on the stock. Wall Street Zen upgraded shares of MetaVia from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. HC Wainwright dropped their target price on MetaVia from $40.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, March 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MetaVia in a research report on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $26.50.

MetaVia Price Performance

Shares of NASDAQ MTVA opened at $1.25 on Thursday. The company has a 50-day moving average price of $1.70 and a 200-day moving average price of $6.66. The stock has a market capitalization of $2.75 million, a P/E ratio of -0.15 and a beta of 0.35. MetaVia has a 1 year low of $1.17 and a 1 year high of $23.10.

Institutional Trading of MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC acquired a new position in MetaVia Inc. (NASDAQ:MTVA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia at the end of the most recent quarter. 1.37% of the stock is owned by institutional investors and hedge funds.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.